What is Alterome?
Alterome Therapeutics operates at the intersection of structural biology and medicinal chemistry, specializing in the development of first-in-class small molecule inhibitors. By focusing on challenging cancer targets such as AKT and KRAS, the company addresses critical gaps in the oncology landscape. Their structure-guided approach allows for the design of highly selective therapies, aiming to improve patient outcomes while minimizing off-target toxicities. As a clinical-stage entity, Alterome is transitioning from foundational research to rigorous human trials, establishing itself as a key player in the next generation of targeted cancer care.
How much funding has Alterome raised?
Alterome has raised a total of $132M across 1 funding round:
Series B
$132M
Series B (2024): $132M, investors not publicly disclosed
Key Investors in Alterome
Undisclosed Investor
An undisclosed institutional partner providing strategic capital to support the advancement of clinical-stage oncology programs.
Undisclosed Investor
A private investment entity focused on long-term growth within the biotechnology and life sciences sector.
Undisclosed Investor
A venture capital firm specializing in early-to-mid stage therapeutic development and precision medicine innovation.
What's next for Alterome?
The infusion of capital from this major strategic investment will primarily support the advancement of Alterome's lead programs through critical clinical milestones. Management is expected to prioritize the expansion of their internal research capabilities and the scaling of clinical trial operations. By leveraging this financial backing, the company aims to solidify its competitive position in the precision medicine sector, potentially attracting further institutional interest as it moves toward data readouts. The strategic focus remains on validating their novel therapeutic candidates in patient populations with high unmet medical needs, thereby enhancing the company's long-term value proposition in the global biotechnology market.
See full Alterome company page
